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Introduction: Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disease characterized by
recurrent self-limiting fever and serositis that mainly affects Mediterranean populations. Many patients with FMF
have been reported in Japan due to increasing recognition of this condition and the availability of genetic analysis
for the gene responsible, MEFV. The present study was performed to elucidate the clinical characteristics of
Japanese FMF patients and to examine the precise genotype-phenotype correlation in a large cohort of Japanese
FMF patients.
Methods: We analyzed the MEFV genotypes and clinical manifestations in 116 patients clinically diagnosed as
having FMF and with at least one mutation.
Results: The most frequent mutation in Japanese patients was E148Q (40.2%), followed by M694I (21.0%), L110P
(18.8%), P369S (5.4%), and R408Q (5.4%). In contrast, common mutations seen in Mediterranean patients, such as
M694V, V726A, and M680I, were not detected in this population. The clinical features with M694I were associated
with more severe clinical course compared to those seen with E148Q. P369S/R408Q showed variable phenotypes
with regard to both clinical manifestations and severity. Patients with M694I showed a very favorable response to
colchicine therapy, while those with P369S and R408Q did not.
Conclusions: Clinical features and efficacy of treatment in Japanese FMF patients vary widely according to the
specific MEFV gene mutation, and therefore genetic analysis should be performed for diagnosis in cases of
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Familial Mediterranean fever (FMF) is an autosomal re-
cessive disorder characterized by recurrent, self-limiting
episodes of fever accompanied by peritonitis, pleuritis,
synovitis, and erysipelas-like skin lesions [1]. The patients
having severe FMF attacks sometimes develop lethal renal
amyloid A (AA) amyloidosis. Typical FMF attacks usually
last for approximately 3 days, and they vary in frequency
from once a week to several times per year. Oral colchicine
therapy is quite effective for preventing attacks and the
development of reactive AA amyloidosis. The gene respon-
sible, MEFV, maps to the short arm of chromosome 16
and encodes a protein of 781 amino acids called pyrin
[2,3]. Though the mechanism of pyrin action is still de-
bated, it is considered to be a negative regulator of inflam-
mation [4].
FMF affects more than 100,000 people around the world,
and is particularly prevalent in the Mediterranean basin,
occurring most commonly in Turks, Arabs, Armenians,
and Jews. Five mutations, M694V, V726A, M680I, M694I
(in exon 10), and E148Q (in exon 2), account for 74% of
FMF mutations [5]. However, increasing numbers of cases
have been reported in different ethnic groups and coun-
tries [6]. In Japan, cases of FMF with MEFV mutations
were first reported in 2002 [7], and large numbers of FMF
patients have been reported since even in Japan [8-13]. In
addition, we described the clinical manifestations of FMF
in 80 Japanese patients [14]. This study indicated that the
severity of FMF is milder in Japanese than Mediterranean
patients, with a lower frequency of AA amyloidosis, and
the mutations are also different between Japanese and
Mediterranean patients. However, FMF is still thought of
as an uncommon disease in Japan, and the detailed clinical
features associated with each type of MEFV mutation in
Japanese patients have not been elucidated. To date, a
number of clinical diagnostic criteria have been used to
make a diagnosis of FMF [15-18]. However, it is possible
that some Japanese patients would not meet these diag-
nostic criteria as they are based on the symptoms seen in
Mediterranean patients. Therefore, many patients may
remain undiagnosed and a comprehensive diagnosis, in-
cluding genetic analysis, may be necessary especially in
countries outside the Mediterranean area, such as Japan.
The present study was performed to examine the precise
relationships between each type of MEFV mutation and
clinical manifestations in a large cohort of Japanese FMF
patients. Moreover, we reconsidered the validity of
the existing diagnostic criteria based on the genotype-
phenotype correlation seen in Japanese FMF.
Materials and methods
Patients
MEFV mutation analyses were conducted on genomic
DNA obtained from blood samples in patients withsuspected FMF between September 2003 and December
2012. All patients provided informed consent prior to the
genetic study for DNA testing of the MEFV gene and pub-
lication of their individual details under anonymity. A total
of 216 patients from various hospitals in Japan were
referred to our department for MEFV gene analyses.
Clinical diagnosis of FMF was made according to the
Tel-Hashomer criteria [15]. The major criteria are: 1) re-
current febrile episodes accompanied by peritonitis, syno-
vitis, or pleuritis; 2) amyloidosis of the AA-type without
predisposing disease; and 3) favorable response to colchi-
cine treatment. Minor criteria were: 1) recurrent febrile
episodes; 2) erysipelas-like erythema; and 3) FMF in a
first-degree relative. Patients were divided into two groups
based on the confidence of diagnosis: definitive FMF (two
major or one major and two minor) and probable FMF
(one major and one minor). A definitive or probable diag-
nosis could not be made in some cases despite recurrent
febrile or painful episodes. To examine the genotype-
phenotype correlations of Japanese FMF patients, we in-
cluded a third group called suspected FMF (one major or
one minor), as described previously [19]. In 216 patients,
76 were clinically evaluated by FMF experts in our hos-
pital. Other 140 patients were evaluated by physician con-
tributors throughout Japan using our original clinical
survey sheet for FMF. Based on the clinical information,
we have carefully assessed and determined the groups
(definitive, probable, and suspected) in each patient. All
the genetic analyses were conducted only in our hospital.
Of the 216 patients, 147 carried certain MEFV mutation
(s). Among these, 14 subjects were excluded on the basis
of being asymptomatic family members of FMF patients.
Moreover 17 patients were excluded due to the presence
of different diseases: Behçet’s disease (n =5), inflammatory
bowel disease (n =2), and sarcoidosis, mixed connective-
tissue disease, adult-onset Still’s disease, granulomatosis
with polyangiitis, pseudogout, malignant lymphoma, in-
fectious spondylitis, intercostal neuralgia, mental disorder,
and temperature instability (n =1) (Additional file 1). Con-
sequently, we studied the clinical pictures and types of
MEFV mutations of the remaining 116 patients. Among
them, 39 patients who were diagnosed at our University
and presented in our previous report [14] were included
in this analysis. On the other hand, 69 patients had no
mutation in the MEFV gene. Of 69 patients, 4 patients
were definitive, 1 was probable, 39 were suspected, and 25
were not eligible according to the Tel-Hashomer criteria.
This study was carried out in accordance with Institu-
tional Review Board approval (No. 314) in the Shinshu
University School of Medicine, Nagano, Japan.
DNA testing of the MEFV gene
DNA analysis of the MEFV gene was performed in all
216 patients with suspected FMF. The five hotspot
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were analyzed by PCR [20]. Exon 2 was amplified in two
overlapping PCR fragments, designated as exon 2a and
exon 2b. Amplified PCR products were analyzed by direct
sequencing (DNA Analyzer 3730xl; Applied Biosystems,
Foster City, CA, USA). Primers for PCR and sequence
analysis were as follows: Exon 1 : 5'-TCC TAC CAG AAG
CCA GAC AG-3′; Exon 1R: 5′-TTC CTG AAC TAA
AGT CAT CT-3′; Exon 2aF: 5′-GCA TCT GGT TGT
CCT TCC AGA ATA TTC C-3′; Exon 2aR: 5′-CTT TCC
CGA GGG CAG GTA CA-3′; Exon 2bF: 5′-CAG GCC
GAG GTC CGG CTG CG-3′; Exon 2bR: 5′-CTT TCT
CTG CAG CCG ATA TAA AGT AGG-3′; Exon 3F: 5′-
GAA CTC GCA CAT CTC AGG C-3′; Exon 3R: 5′-AAG
GCC CAG TGT GTC CAA GTG C-3′; Exon 5F: 5′-TAT
CGC CTC CTG CTC TGG AAT C-3′; Exon 5R: 5′-CAC
TGT GGG TCA CCA AGA CCA AG-3′; Exon 10F: 5′-
CCG CAA AGA TTT GAC AGC TG-3′; Exon 10R: 5′-
TGT TGG GCATTC AGT CAG GC-3′.
Statistical analysis
We considered that to include more than 10 patients in
each genotype was appropriate for statistical analysis. All
data are expressed as the mean ± SD for continuous vari-
ables. Multiple differences between groups were compared
by one-way analysis of variance (ANOVA) followed by
Tukey’s post hoc test. Differences between categorical vari-
ables were analyzed using the chi-square test. In all analyses,
P <0.05 was taken to indicate statistical significance. The





















Among the 116 patients, 2 (1.7%) were homozygous, 67
(57.8%) were compound heterozygous, and 47 (40.5%)
were heterozygous for MEFV mutations. Table 1 shows
the distribution of MEFV mutations in this cohort.
Complex alleles were observed in 32 (27.6%) patients.
The detected mutations were E148Q (40.2%), M694I
(21.0%), L110P (19.9%), P369S (5.4%), R408Q (5.4%),
R202Q (4.5%), E84K (2.2%), S503C (1.9%), and G304R
(0.9%). Repartition of the mutations in Japanese patients
and comparison with findings in the four classically
affected ethnic groups, that is, Turks, Arabs, Armenians,
and Jews, are shown in Figure 1. Although M694V,
V726A, and M680I are common mutations in the above
four ethnic groups [22-27] these mutations were not de-
tected in our study population.
Clinical features
The male/female ratio in our study population was 51:65.
The mean age at onset of symptoms was 23.7 ± 13.6 years,
the mean frequency of attacks was 11.7 ± 11.3 per year,
and the mean duration of attacks was 4.7 ± 7.7 days. The
main clinical symptoms of the patients were as follows:
high-grade fever with temperature >38°C was observed in
83.6% of the patients, peritonitis in 62.1%, pleuritis in
45.7%, arthritis in 41.4%, headache in 19.8%, myalgia in
11.2%, rash or erysipelas-like erythema in 6.8%, and
amyloidosis in 1.7% of patients. Among the 116 patients,



















Figure 1 MEFV mutations in Japanese populations and Mediterranean populations [22-27]. n, number of patients with familial Mediterranean
fever (FMF).
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(occasional attacks). The average dosage of colchicine was
0.8 mg/day (0.25 to 2.0 mg/day); 51.6% of the patients re-
ceived <0.5 mg/day and 84.4% received <1.0 mg/day.
Genotype-phenotype correlation
The genotype-phenotype correlation of all patients was
evaluated in more than three patients with same muta-
tion (Table 2), and in one or two patients with the same
mutation (Additional file 2). We next examined the
features of attacks according to age at onset, frequency,
and duration of attacks. In the majority of patients car-
rying the M694I mutation (E148Q/M694I, L110P/E148Q/
M694I, or M694I/wild-type), the age at onset was before
30 years, which was younger than for the other genotypes
(Figure 2A). A portion of the patients who were not car-
rying M694I mutation had an age at onset >30 years and
the disease developed in a few patients after age 40 years.
The frequency of attacks in each genotype is shown inFigure 2B. More than 40% of patients carrying E148Q/
wild-type experienced up to three attacks per year.
Figure 2C shows the durations of attacks. Typically, the
attacks in FMF patients resolve within 3 days [18], but
the attacks lasted over 4 days in a number of patients.
While attacks in all patients with M694I/wild-type im-
proved within 3 days, 50.9% of patients not carrying this
mutation had duration over 4 days.
We also analyzed the frequency of each symptom (fever,
peritonitis, pleuritis, and arthritis). While high-grade fever
(febrile episode; Figure 3A) was the most frequently ob-
served symptom in each genotype group, 50% of the pa-
tients carrying L110P-E148Q/E148Q were afebrile or had
low-grade fever. Peritonitis was observed in 92.3% of
patients carrying M694I/wild-type, which was signifi-
cantly higher than the patients carrying E148Q/wild-type
(Figure 3B). Pleuritis was seen in over 60% of patients car-
rying the M694I mutation, but in under than 50% of those
without this mutation (Figure 3C). Arthritis was observed
Table 2 Genotype-phenotype correlations in more than three patients with the same mutation
Patients,
number
Age at onset, years Frequency of attacks per year Duration of
attacks (days)
Fever ≥38°C Peritonitis Pleuritis Arthritis Efficacy of
colchicine
Mean (± SD) Range Median (min, max) Median (min, max) % % % % %
E148Q/M694I 15 18.8 ± 7.8 9 to 34 12 (2.5, 54) 2.5 (0.75, 8.5) 93.3 66.7 66.7 26.7 100 (n = 11)
L110P/E148Q/M694I 14 20.4 ± 8.7 13 to 46 12 (2, 30) 3 (2, 7) 85.7 85.7 78.6 50 100 (n = 12)
M694I/wild-type 13 20.2 ± 11.4 3 to 42 9 (3, 48) 2.5 (0.08, 3) 92.3 92.3 61.5 30.8 100 (n = 12)
L110P/E148Q 13 15.2 ± 11.6 2 to 48 5.5 (1.5, 18) 3.3 (1, 17.5) 84.6 69.2 0 38.5 83.3 (n = 6)
L110P-E148Q/E148Q 6 35.5 ± 15.1 18 to 65 12 (3, 12) 5 (0.75, 8.5) 50 66.7 50 16.7 100 (n = 3)
E148Q/wild-type 21 26.5 ± 12.1 7 to 61 4 (1, 24) 2.5 (1, 75) 81 52.4 42.3 47.6 81.8 (n = 11)
P369S/R408Q 4 35.5 ± 16.7 14 to 60 24 (6, 48) 5.8 (0.2, 19) 75 25 25 50 50 (n = 2)
L110P/E148Q/ P369S/R408Q 4 18.3 ± 8.9 6 to 31 18 (5, 24) 4 (2.5, 7) 100 25 50 25 50 (n = 2)
R202Q/wild-type 8 32.4 ± 19.4 11 to 68 15 (4, 48) 5.8 (1, 14) 87.5 50 25 75 33.3 (n = 3)
E84K/wild-type 3 20.7 ± 6.2 14 to 29 4 (2, 12) 3 (1.5, 3.5) 100 0 33.3 33.3 NE















Figure 2 Genotype-phenotype correlation of 116 Japanese familial Mediterranean fever (FMF) patients. (A) Age at onset of each
genotype in years (y.o.). (B) Frequency of attacks in each genotype (times per year). (C) Duration of attacks in each genotype (days). (D) Efficacy
of colchicine therapy in each genotype. Complete response means asymptomatic, Good response means occasional attacks.
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symptom was only seen in fewer than 50% of patients with
other genotypes.
Next, we evaluated the efficacy of colchicine therapy in
each genotype group (Table 2, Figure 2D). Patients car-
rying the M694I mutation had an efficacy rate of 100%
(complete response or good response). Colchicine therapy
had good efficacy in patients with the L110P and/or
E148Q mutation (L110P/E148Q, L110P-E148Q/E148Q,
and E148Q/wild-type), although its rate of use was
approximately 50%. In contrast, this treatment regimen
had insufficient efficacy in patients with P369S/R408Q or
R202Q/wild-type.
One patient with E148Q/M694I received a TNF-α recep-
tor antagonist infliximab and low-dose methotrexate ther-
apy because of colchicine intolerance for adverse events
[28]. Further, some patients with the MEFV gene mutations
were refractory to colchicine and had atypical symptoms of
FMF. To these patients, certain biological drugs such as
TNF-α and IL-1 receptor antagonists might be effective.Finally, we examined the diagnostic rate using the Tel-
Hashomer criteria in our patients with MEFV mutations
(Figure 4). According to these criteria, 88.1% of patients
carrying the M694I mutation matched the definitive
diagnosis, while this was true for only 64.4% of patients
without M694I as a probable or suspected diagnosis. In
particular, large numbers of patients in the P369S/
R408Q, R202Q/wild-type, and E84K/wild-type groups
matched the criteria for a suspected diagnosis (Figure 4).
Discussion
In this study, we examined the frequency of MEFV muta-
tion, clinical manifestations, and the genotype-phenotype
correlations in 116 Japanese patients with FMF. The cli-
nical features of the Japanese patients were different from
those seen in Mediterranean populations. Compared to
Mediterranean patients, Japanese patients had late onset
of symptoms, relatively low frequency of peritonitis, rar-
ity of reactive AA amyloidosis, and low dosage of col-
chicine [14]. The results of the present study suggest
Figure 3 Frequency of symptoms in each genotype. High-grade fever (febrile episodes) (A), peritonitis (B), pleuritis (C), and arthritis (D). More
than 10 patients in each genotype was used for the statistical analysis. *P <0.05.
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Mediterranean populations are associated with diffe-
rences in genotype. Over 280 sequence variants in the
MEFV gene have been recorded in the Infevers database
[29], the most common of which are M694V, M694I,
V726A, M680I, and E148Q [5,19,30]. These five muta-
tions account for approximately 90% of sequence vari-
ants in classically affected ethnic groups (Turks, Arabs,
Armenians, and Jews) (Figure 1). However, only 61.2%
of Japanese FMF patients in the present study had
E148Q and/or M694I, and none of our patients had
M694V, V726A, or M680I. Especially, M694V, which is
related to the most severe clinical course [19,30], has
not been detected in Japanese patients. On the other
hand, the largest number of Japanese patients with the
E148Q mutation had a mild clinical course [5]. It has
been suggested that FMF, along with Behçet’s disease,
may have been transmitted to Japan via travel along the
Silk Road [6]. However, this hypothesis cannot explain
the differences in mutation types between Japan andMediterranean regions and the low prevalence of FMF,
compared to Behçet’s disease, which is a common dis-
ease in Japan. As an island nation, Japan has a number
of intrinsic disease features and Japanese patients have
specific clinical presentations and mutation types.
As shown in Tables 1 and 2, the majority of Japanese
FMF patients had some combination of M694I, E148Q,
L110P, P369S/R408Q, and R202Q mutations. The pre-
sence of M694I in exon 10 is thought to be important
for diagnosis and treatment. Patients with this mutation
show a typical and severe clinical course, with early on-
set, high frequency and short duration of attacks, and
high percentages of fever and serositis. However, their
therapeutic response to colchicine is very good. Hence,
identification of the M694I mutation is a useful diagnos-
tic foundation for Japanese patients with suspected FMF.
E148Q has been considered to be a polymorphism be-
cause its allele frequency is high in healthy controls [31].
In Japan, it has been reported that allele frequency of
E148Q, L110P, and M694I are 0.26, 0.039, and 0.0,
Figure 4 Confidence of diagnosis based on the Tel-Hashomer criteria in each genotype.
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indicated that most homozygous or compound heterozy-
gous patients associated with other MEFV mutations are
symptomatic and their clinical course is relatively mild
[5,32]. In the present study, the clinical manifestations of
patients with E148Q were later onset, lower frequency,
and slightly longer duration of attacks, compared to
patients with M694I. Moreover, some patients hetero-
zygous only for E148Q presented with typical FMF
manifestations. Generally, it is difficult to make a de-
finite diagnosis in patients heterozygous for only E148Q.
In such cases, a comprehensive diagnosis including not
only the clinical course but also the efficacy of colchicine
may be required.
The L110P mutation was always compound heterozy-
gous with E148Q mutation, and there were no patients
heterozygous for L110P alone. This mutation was identi-
fied commonly in our study and several cases of FMF
with this mutation have been reported in Japan [33,34].
Although L110P may be a frequent mutation, especially
in Japanese patients, there were no marked differences
in the clinical picture between L110P/E148Q and E148Q
alone.
In addition, it may be necessary to pay special attention
to the diagnosis in patients with P369S/R408Q mutations
in exon 3. P369S and R408Q are always identified in cis
[35], as observed in our study. In the present study, 12 pa-
tients with P369S/R408Q (alone or with additional mu-
tations) were identified, and their clinical features were
characterized by a high frequency of attacks, variablephenotype, and incomplete efficacy of colchicine therapy.
The mean frequency of attacks in these 12 patients was
22.5 times per year. Their clinical symptoms were highly
variable: four were variable in frequency or duration of at-
tacks, two experienced frequent abdominal attacks with-
out high fever and elevation of serum C-reactive protein
(CRP) level, and other findings. Eight patients received
colchicine therapy, but four had only a partial response,
and the others showed no response. Ryan et al. report that
patients with P369S/R408S mutations have clinical diver-
sity, atypical clinical presentation, and relative lack of
response to colchicine treatment [35]. This report is com-
parable to the phenotype in our patients with P369S/
R408S. Therefore, it will be necessary to establish other
more effective therapies, including biological treatment,
for such cases.
As indicated in the present study, there were dif-
ferences in clinical characteristics between the various
MEFV mutations. As the majority of patients with
M694I have typical FMF symptoms, identification of this
mutation can lead to a definite diagnosis. When other
mutations, such as E148Q and/or L110P, P369S/R408Q,
R202Q, E84K, S503C, or G304R are identified, a com-
prehensive diagnosis including the efficacy of colchicine
treatment may be required. Therefore, it is important to
perform MEFV gene analysis for diagnosis of patients
with suspected FMF (recurrent febrile episodes and/or
serositis, and exclude diagnosis of other diseases). After
treatment with colchicine, it is important to examine the
diagnostic validity. The possibility of FMF cannot be
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tions, but a careful colchicine trial is required.
Conclusions
The results of the present study indicated that the clinical
characteristics and MEFV genotypes of Japanese FMF
patients are different from those seen in Mediterranean
populations. Our clinical data established a spectrum of
MEFV mutations among Japanese patients. As clinical
features and efficacy of treatment vary widely according to
the mutation(s) present, comprehensive diagnosis in-
cluding clinical data and genetic analysis is needed for
Japanese FMF patients.
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